The systematic performance and review of autopsies of bone marrow transplant recipients has proved to be quire helpful in the evaluation and appropriate modification of experimental protocols. The autopsies performed for the John Hopkins Hospital Bone Marrow Transplant Unit differ from routine autopsies in that multiple cultures are performed for infectious agents (virus, fungus, bacteria) and additional biopsies of tissue are evaluated for graft-vs-host disease, immune reconstitution, relapse of leukemia, toxicity, etc. In this proposal, we will continue to perform and review the autopsies as part of the evaluation of the experimental protocol described elsewhere.
The specific aims for this section of the core project are: 1. To assist in evaluating the effectiveness of the experimental protocol, such as prevention of relapse of malignancy or prevention of acute and chronic GvHD. 2. Systematic evaluation for complications including infectious diseases and drug toxicity. The autopsies will be reviewed by a single pathologist (WEB) discussed regularly at monthly morbidity and mortality conferences.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA015396-23
Application #
5206713
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
23
Fiscal Year
1996
Total Cost
Indirect Cost
Schoch, Laura K; Cooke, Kenneth R; Wagner-Johnston, Nina D et al. (2018) Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2:2226-2229
Kasamon, Yvette L; Fuchs, Ephraim J; Zahurak, Marianna et al. (2018) Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. Biol Blood Marrow Transplant 24:1022-1028
Robinson, Tara M; Prince, Gabrielle T; Thoburn, Chris et al. (2018) Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients. Leuk Lymphoma 59:2801-2811
Grant, Melanie L; Bollard, Catherine M (2018) Cell therapies for hematological malignancies: don't forget non-gene-modified t cells! Blood Rev 32:203-224
Ghosh, Nilanjan; Ye, Xiaobu; Tsai, Hua-Ling et al. (2017) Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma. Biol Blood Marrow Transplant 23:1903-1909
Majzner, Robbie G; Mogri, Huzefa; Varadhan, Ravi et al. (2017) Post-Transplantation Cyclophosphamide after Bone Marrow Transplantation Is Not Associated with an Increased Risk of Donor-Derived Malignancy. Biol Blood Marrow Transplant 23:612-617
Alonso, Salvador; Jones, Richard J; Ghiaur, Gabriel (2017) Retinoic acid, CYP26, and drug resistance in the stem cell niche. Exp Hematol 54:17-25
Cruz, Conrad R Y; Bollard, Catherine M (2017) Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells. Curr Drug Targets 18:271-280
Fuchs, Ephraim Joseph (2017) Related haploidentical donors are a better choice than matched unrelated donors: Point. Blood Adv 1:397-400
Kanakry, Christopher G; BolaƱos-Meade, Javier; Kasamon, Yvette L et al. (2017) Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood 129:1389-1393

Showing the most recent 10 out of 456 publications